Senate Bill No. 1324 authorizes emergency medical services (EMS) personnel to administer glucagon nasal powder, a medication used to treat severe hypoglycemia in individuals with diabetes. The bill defines "emergency medical services personnel" to include certified emergency medical responders, various classes of certified emergency medical technicians (EMTs), including advanced EMTs, and licensed paramedics. To administer glucagon nasal powder, EMS personnel must be trained according to national standards recognized by the Commissioner of Public Health and must determine that its use is necessary for the patient. The bill mandates that all EMS personnel receive this training from an organization designated by the commissioner and allows licensed or certified ambulances to carry glucagon nasal powder for administration.

The bill introduces new legal language that specifies the training requirements and the definition of glucagon nasal powder, while no existing legal language is deleted. The potential fiscal impact includes costs for the University of Connecticut, UConn Health, and various municipalities due to the acquisition of glucagon nasal powder and the training of EMS personnel. The glucagon nasal powder is estimated to cost approximately $300 per unit, and the overall financial implications will depend on the usage rate and the ability to incorporate the training into existing EMS curricula without significantly increasing costs. The bill is set to take effect upon passage.